STATCenter·
STAT+: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study
Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.
Read at STAT →
Health · 1 sources covering this
STAT+: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study
Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.
Coverage spectrum
0 L · 1 C · 0 R
